Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Study Objectives Primary: To determine MTD and dose limiting toxicities (DLTs) of IOP
magnetic resonance imaging (MRI) contrast agent in healthy subjects.
Secondary:
1. To characterize the pharmacokinetic profiles of IOP MRI contrast agent in healthy
subjects.
2. To evaluate safety/tolerability profiles of IOP MRI contrast agent in healthy subjects.
3. To explore efficacy profiles of IOP MRI contrast agent for liver organ in healthy
subjects.